Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 8731 https://www.adaptimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics PLC -

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday - May 17th, 2022 9:03 pm
Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT - May 16th, 2022 9:00 pm
Adaptimmune Reports First Quarter Financial Results and Business Update - May 9th, 2022 11:30 am
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer - May 4th, 2022 12:00 pm
Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022 - Apr 28th, 2022 8:30 pm
New Strong Sell Stocks for April 26th - Apr 26th, 2022 11:24 am
New Strong Sell Stocks for April 22nd - Apr 22nd, 2022 1:03 pm
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today - Apr 19th, 2022 7:43 pm
Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday - Apr 11th, 2022 8:40 pm
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors - Apr 8th, 2022 5:00 pm
New Strong Sell Stocks for March 25th - Mar 25th, 2022 11:18 am
Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left? - Mar 14th, 2022 3:31 pm
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update - Mar 14th, 2022 12:00 pm
Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal - Mar 8th, 2022 9:14 pm
Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022 - Mar 8th, 2022 5:36 pm
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag - Mar 2nd, 2022 4:22 pm
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss - Mar 2nd, 2022 4:16 pm
After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP) - Mar 2nd, 2022 3:00 pm
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag - Feb 24th, 2022 7:49 pm
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat - Feb 18th, 2022 3:29 pm